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Abstract
Objectives. Cardiovascular (CV) mortality in RA patients is 50% higher than in the general population. There is
increasing recognition that systemic inflammation is a major driver of this. IL-6 is implicated in cardiovascular dis-
ease (CVD) in the general population but its role in CVD in RA is undefined. Of the two modes of IL-6 signalling,
trans-signalling is pro-inflammatory whereas classical signalling is linked with inflammation resolution. This study
examines the role of IL-6 trans-signalling in CVD in a mouse model and patients with RA.
Methods. Myography determined the effect of IL-6 trans-signalling blockade, using sgp130Fc, on aortic constric-
tion in murine collagen-induced arthritis. Serum CCL2 and sVCAM-1 as soluble biomarkers of sIL-6R trans-signal-
ling were investigated in a human cross-sectional study. An observational longitudinal study investigated the asso-
ciation between these biomarkers and progression of subclinical atherosclerosis in early RA by measuring carotid
intima-media thickness (CIMT).
Results. sgp130Fc reduced arthritis severity, serum CCL2 and sVCAM-1 and restored vascular function in
collagen-induced arthritis (CIA). In established RA, sVCAM-1 correlated with the 28-joint DAS (DAS28) and CV risk.
In early RA, baseline DAS28 was associated with CIMT change at 6 months. CIMT ‘rapid progressors’ at 12 months
had higher baseline sVCAM-1, haemoglobin A1c, cholesterol:high-density lipoprotein cholesterol ratio and LDL
cholesterol.
Conclusions. IL-6 trans-signalling plays a pivotal role in vascular dysfunction in CIA. In early RA, sVCAM-1 was
associated with progression of subclinical atherosclerosis. Inflammation from RA onset in CVD-susceptible individu-
als may accelerate atherosclerosis. IL-6 trans-signalling blockade may be beneficial to RA patients and perhaps for
atherosclerosis in the general population.
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Introduction
Cardiovascular (CV) mortality in patients with RA is 50%
higher than in the general population [1]. Although well
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. IL-6 trans-signalling blockade using spg130Fc improved arthritis severity and restored vascular function in murine
CIA.
. In early RA, baseline sVCAM-1 was higher in patients who developed rapid progression of subclinical
atherosclerosis.
. Blockade of IL-6 trans-signalling is promising for RA and its comorbidity of cardiovascular disease.
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established that the incidence of cardiovascular disease
(CVD) is increased, the precise cause is unclear. There
is increasing recognition that systemic inflammation is a
major driver of increased CV risk [1–3]. CV risk is evi-
dent even before a clinical RA diagnosis is made [4]. IL-
6 is implicated in CVD in the general population but its
role in CVD in RA is not well defined. IL-6 can activate
cells via two signalling pathways, IL-6 classical signalling
and IL-6 trans-signalling. In classical signalling, IL-6
binds to membrane-bound IL-6 receptor (mIL-6R). The
complex of IL-6/mIL-6R associates with the b-signalling
receptor gp130, which dimerizes and instigates intra-
cellular signalling [5]. IL-6R is only present on hepato-
cytes and some leucocyte subpopulations, including
monocytes, neutrophils and some T cells and B cells
[6]. Thus classical signalling only affects certain cells.
In addition to signal transduction through mIL-6R, there
is also ‘trans-signalling’. Here, soluble IL-6R (sIL-6R),
which is generated by either alternative splicing or
ectodomain shedding [7], triggers gp130 signalling by
binding to IL-6R [6]. As gp130 is ubiquitously
expressed, trans-signalling enables IL-6/sIL-6R to acti-
vate cells that lack mIL-6R. Of the two modes of IL-6
signalling, evidence demonstrates that trans-signalling
is pro-inflammatory whereas classical signalling has re-
generative or anti-inflammatory effects [6, 8]. The aim
of this study was to examine the role of IL-6 trans-sig-
nalling in CVD in RA by experimental and translational
studies.
The well-characterized model of murine collagen-
induced arthritis (mCIA) offers a method to study early
systemic inflammatory changes in RA and associated
vascular responses and is considered the gold stand-
ard in vivo model for RA studies [9]. Since increased
CV risk precedes RA onset, mCIA offers an ideal op-
portunity to identify the earliest pathological changes
within the vasculature that could subsequently contrib-
ute to CVD. To mechanistically investigate these tis-
sues in human disease is difficult, if not impossible.
Vascular dysfunction has been described in several
animal models of arthritis, including adjuvant-induced
arthritis [10] and mCIA [11]. We have previously charac-
terized vascular responses in mCIA, observing
decreased constriction responses in aortae [12, 13].
Soluble forms of gp130 (sgp130) are the natural inhibi-
tors of IL-6 trans-signalling [14] and previous studies
found that sgp130Fc improved arthritis severity in
mCIA [15]. To test the hypothesis that targeting IL-6
trans-signalling can improve vascular dysfunction in
mCIA, we used sgp130Fc and observed aortic con-
striction responses ex vivo.
It is difficult to quantify the level of IL-6 trans-signal-
ling in mouse models and RA patients; levels of IL-6,
sIL-6R, sgp130, IL-6/sIL-6R complex and IL-6/sIL-6R/
sgp130 complex can be measured but the affinity of IL-
6 to IL-6R is low, in the range of 1 nM [16]. Therefore
serum proteins linked to IL-6 trans-signalling (VCAM-1
and CCL-2) were measured as potential biomarkers of
both trans-signalling and disease activity and vascular
function in CIA and validated in patients with established
and early RA. VCAM-1 and CCL2 are associated with
CVD in the general population. Previous work using a
BioMAP system found that sIL-6R regulates the release
of VCAM-1 and CCL2 [17].
Rapid progression of CVD occurs soon after RA onset
[18]. Importantly, the current modified systemic coronary
risk evaluation (mSCORE) index recommended by the
EULAR is predicted to underestimate CVD risk in RA
patients [19]. Several validated non-invasive imaging
techniques are now available as surrogate markers for
determining subclinical atherosclerosis in RA [20]. Of
these, ultrasonographic assessment of carotid intima-
media thickness (CIMT) and the presence of plaques is
capable of stratifying RA patients with high CV risk. In
this study, CIMT and CIMT progression over time were
used as surrogate markers of CVD and CVD
progression.
In short, to examine the role of IL-6 trans-signalling
in CVD in RA we investigated whether blocking IL-6
trans-signalling using sgp130Fc, without inhibiting IL-6
classical signalling, restores vascular function in CIA
and whether proteins regulated by IL-6 trans-signalling
(VCAM-1 and CCL-2) are associated with vascular dys-
function in CIA and markers of CVD in RA patients.
Methods
Animals
Experiments were undertaken in 8-week-old male DBA-
1 mice (Charles River, Margate, UK). Procedures were
performed in accordance with Home Office–approved
project license 30/2928 and personal licence I5/
6CC73C0.
mCIA
DBA-1 mice were induced with mCIA as previously
described [9, 21]. Mice were immunized on two occa-
sions, 21 days apart, with 100 mL intradermal injections
of emulsion containing 1 mg/ml type II chicken sternal
collagen and 2.5 mg/ml Freund’s complete adjuvant
(both from Sigma-Aldrich, Gillingham, UK). Temgesic
(0.4 mg/ml) was administered ad libitum via drinking
water on day 20 and continued until the end of each
experiment.
Assessment of arthritis
Joint swelling was assessed daily following immuniza-
tion on day 21 as previously described [9]. Hind paw
swelling was recorded using an analogue micrometre.
Arthritis severity in each paw (paw score) was assessed
using an established scoring system from 0 to 5 [9]
(Supplementary Data S1, available at Rheumatology on-
line). The sum of scores for all four paws provided the
clinical score for each mouse.
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sgp130Fc therapy in CIA
Mice were randomly assigned to one of three treat-
ment groups on day 21. Animals received either i.v.
sgp130Fc (2.5 mg/kg), etanercept (2.5 mg/kg; Amgen,
Cambridge, UK) or PBS on day 21 and day 28 (n! 10
in each group). Mice were killed on day 30. Ten mice
served as age- and sex-matched non-immunized
controls.
Collection of experimental samples for mCIA
At the experimental endpoint, mice were killed by inhal-
ation of CO2. Subsequently the aorta was exposed and
vented in the abdomen. The left ventricle was perfused
with 500 mL physiological Krebs solution (mmol/l: NaCl
10.92, KCl 2.68, KH2PO4 1.78, MgSO4•7H2O 2.49,
NaHCO3 25.10, glucose 10.99, CaCl2•2H2O 1.98). The
thoracic aorta was dissected and immediately placed in
Krebs solution for myography.
ELISA
Approximately 1 ml of whole blood was obtained from
mice after sacrifice. After centrifuging at 4"C at
10 000 rpm for 10 min, 200ml of serum was aliquoted.
Serum CCL2, sVCAM-1 and sgp130 were measured
using ELISA kits (R&D Systems, Abingdon, UK) in ac-
cordance with manufacturer’s instructions.
Assessment of aortic constriction in murine CIA
Myography was used to investigate vascular constriction
to serotonin (5-HT) in isolated sections of thoracic aorta.
Aortic rings without perivascular adipose tissue (2 mm
thick) were bathed in physiological Krebs solution at
37"C and gassed with 95% O2/5% CO2. Rings were set
to baseline tension of 5 mN. Following equilibration,
rings were exposed to 60 mmol/l potassium Krebs
(mmol/l: NaCl 39.36, KCl 59.83, KH2PO4 1.18,
MgSO4•7H2O 2.49, NaHCO3 25.10, glucose 10.99,
CaCl2•2H2O 1.98; Sigma-Aldrich). Once constriction had
reached a plateau, tissues were washed and allowed to
return to baseline tension. Cumulative concentration
responses to 5-HT (1 nmol/l–10 mmol/l) were then per-
formed. Contractile response was measured using
MyoDak software, analysed using MyoData and calcu-
lated as developed tension (in mN).
RA patients
A total of 182 patients with established RA, defined by
ACR/EULAR 2010 criteria [22] and diagnosis >1 year,
were recruited to a cross-sectional study (Research
Ethics Committee for Wales reference no. 12/WA/0045).
Demographic details are shown in Table 1. Forty-five
patients with early RA (symptoms <6 months) were
recruited. Demographic details are shown in Table 2.
Patients were assessed every 6 months for 12 months. A
total of 35 patients were followed up at 6 months and 18
patients were followed up at 12 months. Ethnicity was
91% Caucasian, 4% Indian, 2% Pakistani and 2%
Czech (Research Ethics Committee for Wales reference
no. 11/WA/0326).
TABLE 1 Demographic and clinical data for 182 patients
with established RA
Variables Values
Age, years, mean (S.E.M.) 60 (1.2)
Gender, %
Female 67
Male 33
Disease duration, years, mean (S.E.M.) 13.1 (1.0)
Rheumatoid factor positive, % 63.9
Anti-CCP antibody positive, % 66.3
CRP, mg/l, mean (S.E.M.) 11.9 (2.1)
ESR, mm/h, mean (S.E.M.) 22 (1.7)
DAS28, mean (S.E.M.) 3.6 (0.2)
Systolic BP, mmHg 129 (2.2)
Cholesterol:HDL ratio, mean (S.E.M.) 3.8 (0.1)
QRISK2, %, mean (S.E.M.) 16 (1.5)
Framingham, %, mean (S.E.M.) 13 (0.9)
Taking any DMARD, % 70
Taking methotrexate, % 49
Taking any biologic, % 21
Taking tocilizumab, % 10
Taking corticosteroids, % 22
TABLE 2 Demographic and clinical data for 45 patients
with early RA at baseline
Variables Values
Age, years, mean (S.E.M.) 56.1 (2.2)
Female, % 75
Disease duration, months, mean (S.E.M.) 4.0 (0.2)
RF positive, % 59
Anti-CCP antibody positive, % 75
CRP, mg/l, mean (S.E.M.) 11 (2)
ESR, mm/h, mean (S.E.M.) 24 (3)
DAS28, mean (S.E.M.) 3.87 (0.20)
Extra articular features, % 15
Systolic BP, mmHg, mean (S.E.M.) 136 (3.2)
QRISK2, %,mean (S.E.M.) 16.9 (2.5)
QRISK2 >10%, % 54
Framingham score, %,mean (S.E.M.) 14.5 (2.2)
SCORE, %, mean (S.E.M.) 1.1 (0.4)
Smoking, %
Never smoked 39.5
Former 34.9
Current 25.6
BMI, mean (S.E.M.) 27.3 (0.9)
HbA1c, mmol/mol, mean (S.E.M.) 40.2 (1)
Family history of CVD <60 years, % 18
Taking any DMARD, % 63
Taking methotrexate, % 58
Taking biologics, % 0
Taking two DMARDs, % 30
Taking NSAIDs, % 22
Taking corticosteroids, % 24
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Patient assessments
The 28-joint DAS (DAS28) [23] was calculated. CV risk
was calculated for each patient using the QRISK2,
Framingham and SCORE algorithms.
Carotid US
A total of 45 patients with early RA underwent carotid US.
Examinations were performed by the same investigator in a
quiet, temperature-controlled room. Patients were posi-
tioned supine after resting for 30 min. The left and right com-
mon carotid arteries were imaged longitudinally 1 cm
proximal to the carotid bifurcation. Images were focused on
the posterior wall of the artery and magnified. Several 10 sec
cine loops were recorded in DICOM format and downloaded
for offline analysis, performed by a single observer. An auto-
mated carotid analyser (Carotid Analyzer, Medical Imaging
Applications, Iowa City, IA, USA) was used to measure
CIMT. Three end-diastolic frames were selected and CIMT
measured, defined as the interface between lumen-intima
and media- adventitia, for the right and left carotid arteries.
The mean of three end-diastolic frames was calculated, then
the mean of the left- and right-sided readings was calculated.
The internal and external carotid arteries and bifurcation
were scanned and the presence/absence of plaque noted.
CIMT >0.90 mm and/or carotid plaques were used as the
gold standard test for subclinical atherosclerosis and high
CV risk as per Corrales et al. [24]. These patients were
classed as ‘US positive’. Those without plaque and CIMT
<0.9 mm were ‘US negative’. A previous study by Södergren
et al. [25] in 27 patients with early RA found that the mean in-
crease in CIMT at 18 months was 0.05 mm (S.D. 0.15). For this
study, ‘rapid progressors’ were defined as those who had an
increase in CIMT>0.05 mm. The carotid distensibility coeffi-
cient in 10#3/kPa was calculated using the equation from
Dijk et al. [26]:
$2 % DD=Dd&=PP& % 1000:
Measurement of IL-6, sIL-6R, IL-6/sIL-6R complex,
CCL2 and sVCAM-1
Blood was taken into Vacutainer serum separation tubes
(Becton Dickinson, Franklin Lakes, NJ, USA) and centri-
fuged at 1300–1800 g for 5 min at 4"C. Serum was ali-
quoted and frozen at #80"C. After thawing, IL-6, sIL-6R,
IL-6/sIL-6R complex, CCL2 and sVCAM-1 were meas-
ured using ELISA kits (R&D Systems) in accordance
with the manufacturer’s instructions.
Statistical analysis
Statistics used were dependant on the experiments per-
formed. Variables were checked for normality; normally
distributed data are presented as the mean (S.D.) and
non-normally distributed data are expressed median
(interquartile range). Differences between groups were
analysed using paired (for comparison between the
same patients) or unpaired (for comparison between dis-
tinct test subjects) t-tests for normally distributed data.
Differences between groups with non-normally distrib-
uted data were analysed using the Mann–Whitney U
test. Where multiple groups were compared, a one-way
analysis of variance and post hoc Bonferroni test were
performed. Binary logistic regression was used to exam-
ine the effect of multiple variables on particular out-
comes. Differences with p-values <0.05 were
considered significant. Statistics were calculated using
SPSS version 26 (IBM, Armonk, NY, USA).
Patient and public involvement
Patients were involved in the design and conduct of this
research. A local ambassador for the National
Rheumatoid Arthritis Society was consulted on study
design and updated on study progress and findings.
Results
I.v. sgp130Fc reduced arthritis incidence and
severity in immunized DBA-1 mice and restored
vascular function in CIA
To determine whether blockade of IL-6 trans-signalling
improved arthritis severity and restored vascular function,
i.v. sgp130Fc was administered to mice immunized with
CIA. Arthritis incidence on day 29 was 90% for PBS-
administered mice, 50% for sgp130fc-administered mice
and 50% for etanercept-administered mice (Fig. 1A). The
mean total paw score for PBS-administered mice [4.3 (S.D.
3.4)] was significantly higher than mice administered
sgp130Fc [1.5 (S.D. 1.8)] and etanercept-administered mice
[1.2 (S.D. 1.7), P< 0.05] (Fig. 1B). There was a significant
reduction in maximal developed tension in PBS-
administered mice [5.8 mN (S.D. 2.4)] compared with non-
immunized control mice [8.5 mN (S.D. 1.8), P<0.05]. There
was no significant difference in mean maximal developed
tension between sgp130Fc- [8.1 mN (S.D. 2.0)] and
etanercept-treated [7.7 mN (S.D. 1.9)] mice and non-
immunized controls (Fig. 1C).
sgp130Fc reduced serum CCL2 and sVCAM-1
levels in immunized mice compared with those
administered PBS
Given that sgp130Fc improved indices of arthritis sever-
ity and vascular function during CIA, we measured
serum sVCAM-1 and CCL2, both known to be associ-
ated with atherosclerosis and regulated by IL-6 trans-
signalling [17]. Serum CCL2 was significantly higher in
PBS- [117.3 pg/ml (S.D. 14.5)] and etanercept-
administered [116.7 pg/ml (S.D. 36.7)] mice compared
with sgp130Fc [41.87 pg/ml (S.D. 12.1)] and non-
immunized controls [16.9 pg/ml (S.D. 4.8); P< 0.001]
(Fig. 2A). Serum sVCAM-1 was significantly higher in
PBS-administered mice [3144 ng/ml (S.D. 366)] compared
with controls [1861 ng/ml (S.D. 160)], mice administered
etanercept [2077 ng/ml (S.D. 173) and mice administered
i.v. sgp130Fc [1979 ng/ml (S.D. 136); P< 0.01] (Fig. 2B).
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In immunized DBA-1 mice there was a significant posi-
tive correlation between paw score and both serum
sVCAM-1 and serum CCL2 level.
Serum sVCAM-1 is associated with disease activity
and CV risk in established RA
To evaluate the relevance of sVCAM-1 in clinical dis-
ease, we measured serum sVCAM-1 in 182 patients
with established RA and assessed the relationship be-
tween this and disease activity and CV risk. There was a
significant positive correlation between the DAS28 and
sVCAM-1 (r!0.27, P! 0.017) and between the QRISK2
score and serum sVCAM-1 (r!0.32, P! 0.0025).
Patients defined as low CV risk according to the
QRISK2 had significantly lower serum sVCAM-1 [977 ng/
ml (S.D. 600) vs 1247 (588)] than those classified as high
risk.
FIG. 1 Intravenous sgp130Fc reduced arthritis incidence and severity in immunized DBA-1 mice and restored vascu-
lar function in CIA
(A) Arthritis incidence and (B) paw score over time for mice immunized with CIA and administered i.v. sgp130Fc, eta-
nercept or PBS. There was a significant reduction in mean total paw score at day 30 in mice administered sgp130Fc
or etanercept compared with those administered PBS. (C) Vasoconstriction concentration–response curves to 5-HT in
aortic rings. There was a significant reduction in maximal developed tension in mice with CIA administered PBS com-
pared with non-immunized control mice. No significant difference in mean maximal developed tension was seen be-
tween sgp130Fc- and etanercept-treated mice and non-immunized controls. n! 10 in each group. *P< 0.05.
FIG. 2 sgp130Fc reduced serum CCL2 and sVCAM-1 levels in immunized mice compared with those administered
PBS
(A) Significantly higher serum CCL2 was seen in mice with CIA administered PBS or etanercept compared with
sgp130Fc and non-immunized controls. n!9 in each group. (B) Significantly higher serum sVCAM-1 was seen in
PBS-treated mice compared with controls, mice administered etanercept and mice administered sgp130Fc. n! 10 in
each group. *P<0.05, **P<0.01, ***P<0.001.
IL-6 transignaling in CVD in IA
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Traditional risk factors are higher in carotid US–
positive patients with early RA
A total of 41% of patients were carotid US positive.
These patients had significantly higher age, BMI, systolic
blood pressure (BP), total cholesterol, cholesterol:HDL
ratio and LDL cholesterol as well as higher QRISK2,
Framingham, SCORE and American College of
Cardiology/American Heart Association scores than US-
negative patients (see Supplementary Data S2, available
at Rheumatology online). Multivariate logistic regression
analysis including age, BMI, systolic BP, total choles-
terol, cholesterol:HDL ratio, LDL cholesterol and ESR as
covariates found that total cholesterol, LDL cholesterol,
age, BMI and systolic BP were significant independent
variables.
There was no significant difference in CIMT at
12 months [0.706 mm (S.D. 0.048)] compared with
6 months [0.729 mm (S.D. 0.041)] or baseline [0.708 mm
(S.D. 0.033)]. There were significant positive correlations
between baseline DAS28, baseline CRP, baseline ESR
and baseline QRISK2 and change in CIMT at 6 months
(Fig. 3).
Baseline sVCAM-1 higher in rapid progressors and
those with plaque
Rapid progressors were defined as those who had an
increase >0.05 mm in CIMT; 3 of 18 patients (17%)
were classified as rapid progressors at 12 months.
Baseline total cholesterol, cholesterol:HDL ratio, LDL
cholesterol, haemoglobin A1c (HbA1c) and sVCAM-1
were significantly higher in rapid progressors compared
with non-rapid progressors (Fig. 4). Baseline QRISK2,
Framingham and SCORE scores were significantly
higher in rapid progressors and the arterial distension
coefficient was significantly lower in rapid progressors
(see Supplementary Data S3, available at Rheumatology
online).
FIG. 3 Significant positive correlation between the change in CIMT at 6 months and (A) baseline DAS28 (r!0.50,
P!0.006), (B) baseline CRP (r! 0.51, P!0.006), (C) baseline QRISK2 (r!0.42, P! 0.02) and (D) baseline ESR
(r!0.45, P!0.016).
Ruth Davies et al.
6 https://academic.oup.com/rheumatology
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/advance-article/doi/10.1093/rheum
atology/keaa725/6031452 by guest on 06 January 2021
Baseline sVCAM-1 was significantly higher in those
with plaque at baseline [1049 ng/ml (S.D. 315) vs those
without plaque at baseline [653 ng/ml (S.D. 436)].
Baseline sVCAM-1 was also significantly higher in those
with plaque at 6 months [1082 ng/ml (S.D. 341)] than
those without plaque at 6 months [547 ng/ml (S.D. 380)].
At both 6 and 12 months, age and LDL cholesterol were
higher in those with plaque, but there was no significant
difference in other variables including IL-6, sIL-6R, CRP,
ESR, IL-6/sIL-6R complex and CCL2.
Discussion
Prior studies have shown that mCIA is associated with
aortic contractile dysfunction [9, 13]. The work here vali-
dates this finding but, for the first time, we show that se-
lective blockade of IL-6 trans-signalling using sgp130Fc
reduces arthritis severity and prevents vascular dysfunc-
tion associated with mCIA. This improvement in vascular
function may be due to the effect of IL-6 trans-signalling
on macrophage recruitment into the vessel wall and sur-
rounding adipose tissue. Previous work by Williams et
al. [22] found that mice with mCIA have increased
macrophages in the aorta and perivascular adipose tis-
sue. Kraakman et al. [27] found IL-6 trans-signalling
recruited macrophages to adipose tissue in high fat
diet–induced obesity in mice and that sgp130Fc pre-
vented macrophage accumulation in adipose tissue. The
improvement in vascular function in mice treated with
sgp130Fc in our study was associated with a reduction
in serum CCL2 and sVCAM-1. The effect of sgp130Fc
on vascular function was similar to TNF-a blockade.
TNF-a can stimulate release of IL-6, but this study did
not directly compare TNF-a with IL-6 trans-signalling in-
hibition on vascular function. However, our results sug-
gest inhibition of IL-6 trans-signalling alone can restore
vascular dysfunction in CIA.
It is known that in early RA, CV risk is increased. We
confirm the high prevalence (41%) of subclinical athero-
sclerosis in patients with early RA. Carotid US–positive
patients had several traditional risk factors that were sig-
nificantly higher than in carotid US–negative patients:
age, BMI, systolic BP, total cholesterol, cholesterol:HDL
ratio and LDL cholesterol. We confirm previous findings
that some traditional risk factors (HbA1c, total choles-
terol, cholesterol:HDL ratio and LDL cholesterol) predict
CIMT progression in early RA. However, we also show
FIG. 4 Significantly higher baseline. (A) total cholesterol [6.7 mmol/L (S.D. 0.2) vs 5.2 (0.3)], (B) cholesterol:HDL ratio
[3.7 (S.D. 0.3) vs 5.5 (0.7)], (C) LDL cholesterol [3.1 mmol/L (S.D. 0.3) vs 4.4 (0.3)], (D) sVCAM-1 [734 ng/ml (S.D. 126) vs
1328 (28)] in rapid progressors compared with non-rapid progressors. (E) Significantly lower arterial distension coeffi-
cient was seen in rapid progressors [18.8 (S.D. 1.8)] compared with non-rapid progressors [11.2 (S.D. 2.2)].
*P<0.05, **P<0.01, ***P<0.001.
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the novel finding that baseline serum sVCAM-1 is ele-
vated in RA patients who become rapid progressors in
terms of subclinical atherosclerosis. This adds weight to
the finding that patients with established RA classified
as high CV risk had higher serum sVCAM-1 than those
classified as low CV risk. It should be noted that the
number of rapid progressors in this study was low, and
further work to validate this finding in larger cohorts is
needed. We also show that patients with plaque at
baseline and at 6 months have higher sVCAM-1, and
baseline disease activity correlates with the change in
CIMT at 6 months. Taken together, these findings sug-
gest that in RA, inflammation from disease onset may
accelerate atherosclerosis in susceptible individuals.
In this study, sVCAM-1 (a product of a shedding reac-
tion by ADAM17 [28], which also sheds TNF-a and IL-
6R [29]), was associated with disease states.
Restoration of vascular function in mice immunized with
CIA and treated with sgp130Fc was associated with
reduced serum sVCAM-1. Serum sVCAM-1 correlated
with disease activity and CV risk in established RA, and
in early RA, baseline sVCAM-1 was higher in patients
who developed rapid progression of subclinical athero-
sclerosis. What remains to be elucidated is whether
serum sVCAM-1 can predict CV events in RA patients.
In addition, these consistent findings of association of
sVCAM-1 in disease states prompt consideration about
the potential role of blockade of sVCAM-1 in the treat-
ment of RA and atherosclerosis.
Studies have consistently shown that tocilizumab
(monoclonal antibody against the IL-6R) is associated
with increased lipid levels in the context of decreased
inflammatory markers in RA patients [30, 31]. The ratio
of LDL:HDL remains stable after treatment with tocilizu-
mab due to the parallel increase of LDL and HDL. The
ENTRACTE study compared the rates of major CV out-
comes in RA patients treated with tocilizumab or etaner-
cept [32]. Total cholesterol, LDL, HDL and triglycerides
increased significantly in the tocilizumab arm compared
with the etanercept arm, but there was no difference in
major CV events over the follow-up of 3.5 years.
Tocilizumab has also been shown to improve endothelial
function, leading to a greater increase of effective myo-
cardial work than conventional DMARDs plus glucocorti-
coids through a reduction of inflammatory burden and
oxidative stress [33]. In a mouse model, serum choles-
terol levels and atherosclerotic lesion formation were
significantly increased in ApoE#/#IL-6#/# mice com-
pared with ApoE#/# and wild-type mice [34].
Conversely, mice with hyperactive gp130/IL-6/STAT3
signalling (gp130F/F:ApoE#/# mice) have reduced aortic
plaque development and triglyceride levels [35]. In an-
other mouse study, sgp130Fc treatment led to signifi-
cant regression of advanced atherosclerosis in Ldlr#/#
mice [36]. In a Swedish cohort of 60-year-olds, the ratio
between functional moieties of IL-6 trans-signalling, IL-
6/sIL-6R and IL-6/sIL-6R/sgp130 was associated with
CV event risk [37]. These observations outline a specific
role for IL-6 in regulating lipid metabolism and CV risk.
The advantage of blocking IL-6 trans-signalling over
IL-6R inhibition (e.g. tocilizumab) is that although the lat-
ter is a very effective treatment for RA, several side
effects have been reported. These include abnormalities
in liver function tests, an increase in infection rates and
a risk of gastrointestinal perforation if the patient has
pre-existing diverticulitis [38]. IL-6R inhibition blocks
both IL-6 classical and trans-signalling, whereas
sgp130Fc uniquely blocks trans-signalling. gp130 is a
shared receptor utilized by several related cytokines,
including IL-6, IL-11, IL-27, leukaemia inhibitory factor,
oncostatin M and cardiotrophin 1. In mammals, gp130
plays a critical role during development and gp130-
deficient mice are embryonically lethal [39]. sgp130Fc
blocks IL-6 trans-signalling by binding to the complex of
IL-6/sIL-6R so that this cannot bind to membrane-
bound gp130. Thus other cytokines can still signal via
gp130, including IL-6. Therefore classical signalling and
its associated regenerative and protective effects can
continue [6].
IL-6 trans-signalling appears to play a pivotal role in
vascular dysfunction in mCIA. Results in mCIA were
more consistent than in human studies in terms of asso-
ciation of disease states with VCAM-1 and CCL-2, likely
due to the fact that RA is more heterogeneous than
mCIA. In humans, VCAM-1, which is regulated by IL-6
trans-signalling, was associated with CV risk scores in
established RA and progression of subclinical athero-
sclerosis in early RA. These findings suggest that block-
ade of IL-6 trans-signalling may be beneficial to RA
patients, and perhaps for atherosclerosis in the general
population. Sgp130Fc successfully underwent phase 1
clinical trials in 2014 and is currently under the name
Olamkicept in phase 2 clinical trials for use in the treat-
ment of inflammatory bowel disease [40]. This could
also have therapeutic applicability in the management of
RA and CVD.
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